Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib vs Imatinib in Newly Diagnosed CP-CML
NCT01650805Phase 3Terminated
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jun 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of ponatinib in chronic myeloid leukemia (CML), sponsored by ARIAD Pharmaceuticals, Inc.. Started Jun 2012; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01650805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01650805.